FRMM
Forum MarketsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The balance sheet improved meaningfully by quarter-end, and the RWA tokenization / ETH-yield strategy could create option value if management turns the pivot into repeatable assets and cash flow.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
Management explicitly warns that failure to commercialize RWA plans could leave the company vulnerable to shell-company style risk again.
Momentum
80
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.20 · Bear $1.90
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum80 · Δ7d +0.2
Value41 · Δ7d +0.1
Sentiment2 · Δ7d +1.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
80
26% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+7.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
2
34% active weight
Current posture
7d trendImproving
Δ7d
+1.1
Δ21d
-5.0
Why this grade
Composite grade F. Momentum 79.8 / Value 41.1 / Sentiment 1.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$80.05M
Beta
1.19
Shares Out
13.21M
P/E (TTM) · Derived
-0.1
P/S (TTM)
24.79
P/FCF (TTM) · Derived
-1.11
Rev YoY
-
EPS YoY
-46.5%
Gross Margin
-
Op Margin
-5445.2%
Net Debt
$48.68M
Current Ratio
6.19
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology